ES2192156A1 - Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina. - Google Patents

Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina.

Info

Publication number
ES2192156A1
ES2192156A1 ES200250016A ES200250016A ES2192156A1 ES 2192156 A1 ES2192156 A1 ES 2192156A1 ES 200250016 A ES200250016 A ES 200250016A ES 200250016 A ES200250016 A ES 200250016A ES 2192156 A1 ES2192156 A1 ES 2192156A1
Authority
ES
Spain
Prior art keywords
cyclobenzaprine
treating
sleep disturbances
disorders
low doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200250016A
Other languages
English (en)
Other versions
ES2192156B1 (es
Inventor
Iredell W Iglehart Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vela Pharmaceuticals Inc
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Publication of ES2192156A1 publication Critical patent/ES2192156A1/es
Application granted granted Critical
Publication of ES2192156B1 publication Critical patent/ES2192156B1/es
Anticipated expiration legal-status Critical
Withdrawn - After Issue legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos y composiciones que comprenden una dosis muy baja de ciclobenzaprina o un metabolito de la misma para prevenir y tratar alteraciones del sueño y enfermedades que se manifiestan con una disfunción del sueño, incluyendo síndrome de fibromialgia, síndrome de fatiga crónica, trastornos del sueño, trastornos del dolor psicogénico, o síndromes de dolor crónico, o síntomas de las mismas. La presente invención se refiere, además, a métodos y composiciones pra tratar alteraciones del sueño, dolor crónico o fatiga en humanos que sufren de síndrome de fibromialgia, síndrome de fatiga crónica, trastornos del sueño, trastornos de dolor psicogénico, síndromes de dolor crónico, usando una dosis muy baja de ciclobenzaprina.
ES200250016A 1999-08-13 2000-08-11 Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina. Withdrawn - After Issue ES2192156B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14888199P 1999-08-13 1999-08-13
US60/148881 1999-08-13

Publications (2)

Publication Number Publication Date
ES2192156A1 true ES2192156A1 (es) 2003-09-16
ES2192156B1 ES2192156B1 (es) 2005-02-16

Family

ID=22527835

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200250016A Withdrawn - After Issue ES2192156B1 (es) 1999-08-13 2000-08-11 Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina.
ES00953996T Expired - Lifetime ES2245944T3 (es) 1999-08-13 2000-08-11 Uso de composiciones para tratar o prevenir alteraciones del sueño utilizando dosis muy bajas de ciclobenzaprina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00953996T Expired - Lifetime ES2245944T3 (es) 1999-08-13 2000-08-11 Uso de composiciones para tratar o prevenir alteraciones del sueño utilizando dosis muy bajas de ciclobenzaprina.

Country Status (18)

Country Link
US (3) US6395788B1 (es)
EP (1) EP1202722B1 (es)
JP (1) JP2003506484A (es)
AR (1) AR025110A1 (es)
AT (1) ATE299369T1 (es)
AU (1) AU6635400A (es)
BR (1) BR0013017A (es)
CA (1) CA2380432A1 (es)
DE (1) DE60021266T2 (es)
ES (2) ES2192156B1 (es)
GB (1) GB2368522A (es)
HK (2) HK1047883A1 (es)
IL (1) IL147777A0 (es)
MX (1) MXPA02001569A (es)
NZ (1) NZ516749A (es)
PT (1) PT1202722E (es)
WO (1) WO2001012175A1 (es)
ZA (2) ZA200200619B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3422800A (en) * 1999-02-18 2000-09-04 Novartis Ag Use of 5-ht3 receptor antagonists
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
GB0312425D0 (en) * 2003-05-30 2003-07-09 Boots Co Plc Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith
JP4578083B2 (ja) * 2003-09-30 2010-11-10 小林製薬株式会社 催眠剤組成物
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
PT1954669E (pt) * 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
WO2007098200A2 (en) * 2006-02-16 2007-08-30 Imthera Medical, Inc. An rfid-based apparatus, system, and method for therapeutic treatment of obstructive sleep apnea
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
SI2125698T1 (sl) 2007-03-15 2016-12-30 Auspex Pharmaceuticals, Inc. Devterirani d9-venlafaksin
EP2197536A1 (en) 2007-10-09 2010-06-23 Imthera Medical, Inc. System and method for neural stimulation
CA2730190A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
BRPI0920548B8 (pt) 2008-10-09 2021-06-22 Imthera Medical Inc aparelho para controlar posição da língua de um paciente
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
JP2013509943A (ja) * 2009-11-10 2013-03-21 イムセラ・メディカル・インコーポレーテッド 舌下神経を刺激して患者の舌の位置を調節するシステム
SMT201700578T1 (it) 2009-11-20 2018-01-11 Tonix Pharma Holdings Ltd Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) * 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
WO2013168004A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
RS63822B1 (sr) 2012-06-15 2023-01-31 Tonix Pharma Holdings Ltd Kompozicije i postupci za transmukoznu apsorpciju
SMT202400324T1 (it) 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
MY186047A (en) 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
WO2019014651A1 (en) 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. ANALOGUES OF CYCLOBENZAPRINE AND AMITRYPTILENE
MX2020006140A (es) * 2017-12-11 2020-08-13 Tonix Pharma Holdings Ltd Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20220117915A1 (en) * 2018-08-20 2022-04-21 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
AU2021253592A1 (en) * 2020-04-08 2022-11-10 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
MX2023005899A (es) 2020-11-20 2023-08-16 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol.
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2121529A1 (en) * 1971-01-05 1972-08-25 Merck & Co Inc Compsns contg cyclobenzaprine and indomethacin - chlordiazepoxide, phenylbutazone oxyphenbutazone or corticosteroid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1339636A (en) * 1917-02-23 1920-05-11 Tulloch Thomas Gregorie Fluid-tight joint for steam-pipes and the like
GB859187A (en) 1958-11-25 1961-01-18 United States Borax Chem Method for preparing substituted tris amino boranes
CA958643A (en) 1970-07-07 1974-12-03 Frosst (Charles E.) And Co. Pharmaceutical compositions containing cyclobenzaprine
AR025111A1 (es) * 1999-08-13 2002-11-06 Janus Pharmaceuticals Inc Metodos y composiciones para tratar trastornos de ansiedad generalizada

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2121529A1 (en) * 1971-01-05 1972-08-25 Merck & Co Inc Compsns contg cyclobenzaprine and indomethacin - chlordiazepoxide, phenylbutazone oxyphenbutazone or corticosteroid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KHOUZAM. Chronic fatigue syndrome. Consultant, Julio 2000, Vol. 40, Nö 8, páginas 1441-1450. Página 1448, columna 1, párrafo 1. *
MILLER, D.R. and SEIFERT, D. Management of fibromyalgia, a distinct rheumatologic syndrome. Clinical Pharmacy, 1987, Vol. 6, Nö 785, páginas 778-786. Página 785, párrafo 3. *
SANTANDREA, S. y col. A double-blind crossover study of two Cyclobenzaprine regimens in primary fibromyalgia syndrome. The Journal of International Medical Research, 1993, Vol. 21, Nö 2, páginas 74-80. Resumen. *

Also Published As

Publication number Publication date
DE60021266T2 (de) 2006-05-24
AU6635400A (en) 2001-03-13
BR0013017A (pt) 2002-04-16
EP1202722A1 (en) 2002-05-08
GB2368522A8 (en) 2002-06-13
GB0202908D0 (en) 2002-03-27
IL147777A0 (en) 2002-08-14
NZ516749A (en) 2004-03-26
US20010046988A1 (en) 2001-11-29
US6541523B2 (en) 2003-04-01
JP2003506484A (ja) 2003-02-18
GB2368522A (en) 2002-05-08
ES2245944T3 (es) 2006-02-01
EP1202722B1 (en) 2005-07-13
ES2192156B1 (es) 2005-02-16
PT1202722E (pt) 2005-11-30
WO2001012175A1 (en) 2001-02-22
HK1047691B (en) 2006-05-12
WO2001012175A8 (en) 2001-05-10
DE60021266D1 (de) 2005-08-18
HK1047691A1 (en) 2003-03-07
ZA200200619B (en) 2003-04-23
US20040029869A1 (en) 2004-02-12
HK1047883A1 (zh) 2003-03-14
AR025110A1 (es) 2002-11-06
ATE299369T1 (de) 2005-07-15
MXPA02001569A (es) 2002-07-02
CA2380432A1 (en) 2001-02-22
US6395788B1 (en) 2002-05-28
ZA200200852B (en) 2003-07-30

Similar Documents

Publication Publication Date Title
GB2368522A (en) Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine
GB2368283A (en) Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
MX342305B (es) Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina.
DK1066036T3 (da) Midler med serotoninrelateret aktivitet til behandling af sövnapnö
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
NO20073419L (no) Oral suspensjon omfattende meloxikam
TW200507830A (en) Bronchodilating β -agonist compositions and methods
FR13C0062I1 (es)
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
GB2333453A (en) Colostrinin and uses thereof
WO2005115547A3 (en) Myricitrin compounds for sleeping disorders
BG106226A (en) A blocking monoclinal antibody to vla-1 and its use for the treatment of inflammatory disorders
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
WO2006098979A3 (en) Aminopterin dosage forms and methods for inflammatory disorders
BG106748A (en) Method and compositions for treating pulmonary diseases
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
TNSN05131A1 (en) New synergistic combination comprising roflumilast and formoterol
MXPA04003851A (es) Antipruriticos.
WO2000006138A3 (en) Use of moclobemide for treating pain and other diseases
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
ZA200208272B (en) Treatment of fibromyalgia and chronic fatigue syndrome.
MXPA01006319A (es) Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica.
TW200517118A (en) Anti tumor agent
UA6738A (uk) Спосіб лікування бронхообструктивного синдрому у хворих на бронхіальну астму та хронічний обструктивний бронхіт
HIGASHIFUSHIMI Desire is, as it is, Bodhi in the “Bodaishingisho” Particularly relationship with “soshitsujikyosho”

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030916

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192156B1

Country of ref document: ES

FA2A Application withdrawn

Effective date: 20051018